Breakthrough in CAR-T Therapy Achieved by Chinese Sun Yat-sen University Cancer Center

Recently, Professor Huang Huiqiang’s team at Sun Yat-sen University Affiliated Cancer Hospital achieved significant progress in a lymphoma patient who relapsed after five lines of chemotherapy. Utilizing CAR-T therapy, the patient has experienced complete remission for over two years, making them one of the patients in China with the longest survival post-CAR-T treatment.

Lymphoma, one of the common blood cancers, has traditionally been treated using a combination of chemotherapy, autologous hematopoietic stem cell transplantation, targeted therapies, and immune-modulating drugs. However, CAR-T cell therapy, an advanced technology in the field of oncology, has emerged as a precise, rapid, and highly effective new treatment method in recent years.

Diffuse large B-cell lymphoma is a prevalent aggressive lymphoma characterized by rapid progression, high mortality rates, and short survival periods. Despite significant therapeutic advancements in recent years, approximately 70% of patients achieve good outcomes and long-term remission through first-line treatments, but around 30% of patients have inadequate responses to treatment, facing difficult-to-cure relapses.

Professor Huang Huiqiang emphasized, “CAR-T cell therapy plays a crucial role in providing new treatment hopes for relapsed and refractory patients who cannot undergo transplantation or have previously undergone ineffective treatments.

It is reported that in the future, Sun Yat-sen University Cancer Center will continue to explore clinical innovative technologies in CAR-T cell therapy, aiming to bring new prospects for numerous patients.

#CARTBreakthrough #CancerResearch #SunYatSenCancerCenter #InnovativeTherapies #MedicalBreakthrough #LymphomaTreatment #PrecisionMedicine #HopeForPatients #CancerSurvivorship #AdvancedOncology #MedicalInnovation #ResearchProgress #ScienceNews #HealthcareAdvancements #ImmunotherapySuccess #Cancer

9 months ago CAR-T , Leukemia

If a child unfortunately gets leukemia, should CAR-T Therapy be considered?

In recent years, CAR-T therapy has gained traction in treating leukemia. A quick search yields numerous articles, many of which describe the miraculous effects of CAR-T.

Is the efficacy of CAR-T therapy really that impressive? Should CAR-T therapy be considered for a child diagnosed with leukemia? Today, let’s unravel these doubts together!

What kind of leukemia patients can undergo CAR-T therapy?

Since most acute leukemia patients are sensitive to chemotherapy, chemotherapy is the preferred initial treatment. Currently, CAR-T therapy is primarily used for refractory and relapsed acute B-cell lymphoblastic leukemia patients.

For cases where 1-2 courses of chemotherapy fail to achieve complete remission (primary refractory), or relapse during chemotherapy, or experience ineffective re-treatment after relapse and re-chemotherapy (refractory relapse), CAR-T therapy is the preferred approach.

Celebrating a decade of being cancer-free for the world’s first leukemia child treated with CAR-T therapy

The world’s first leukemia child cured by CAR-T therapy celebrates 11 cancer-free years

On May 10th each year, Emily Whitehead commemorates the anniversary of her cancer-free survival. This year, she turns 18 and has officially become a nurse, leading a busy and joyful life. With the achievement of this significant milestone, the revolutionary cancer treatment known as CAR-T cell immunotherapy has been officially recognized! She has also become the spokesperson for this epic therapy.

Which CAR-T products are currently on the market?

Since 2017, the approval of the world’s first CAR-T products, Novartis’s Kymriah, and Kite Pharma’s Yescarta by the FDA, has heralded a new era in cell immunotherapy. Presently, there are 10 CAR-T drugs approved for market globally. Additionally, there are over 1,000 CAR-T clinical trials registered worldwide on Clinicaltrials, with nearly 500 projects in mainland China. The primary treatment areas include hematologic malignancies, along with solid tumors such as pancreatic cancer, liver cancer, lung cancer, breast cancer, and colorectal cancer.

More and more people are choosing to seek medical treatment in China. China’s technology in oncology, especially in CAR-T, is now on par with that of the United States. The fundamental reasons why many individuals with related diseases choose China are the high-quality services, pleasant environment, and comparatively affordable prices.

“If you’d like to inquire about the latest cancer-fighting technologies and treatments, you can contact us.”

whatsapp:+8613717959070

#CARTTherapy #CART #Emily #Cancer #cancerfree #cancerkids

#LeukemiaTreatment #CancerFreeAnniversary #ChildhoodLeukemia #Immunotherapy #MedicalInnovation #EmilyWhitehead #CARTProducts #ClinicalTrials #HematologicMalignancies #leukemia